Cyclomics focuses on the development and commercialisation of innovative AI-based cancer diagnostic solutions. Following the development of breakthrough technologies and a long-standing partnership with Oxford Nanopore Technologies, the company is now seeking funding to launch their first products in the clinical market.

Cyclomics is at the verge of commercialising its Epinn technology, a market-read software package encompassing novel AI models for classification of cancer subtypes based on (sparse) DNA methylation data. The technology has been tested across dozens of patients with brain cancer and is featured in major news outlets, including Nature, The New York Times and National Geographic. Derivative products will be developed for other cancer types (leukaemia, sarcoma, oral squamous cell carcinoma), thereby opening even larger market segments.